<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-144-59</article-id>
<article-id pub-id-type="doi">10.26800/LV-144-1-2-8</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group>
</article-categories>
<title-group>
<article-title>Disfunkcija o&#x0161;ita uzrokovana mehani&#x010D;kom ventilacijom &#x2013; patofiziologija i terapijske mogu&#x0107;nosti</article-title>
<trans-title-group xml:lang="en">
<trans-title>Diaphragm dysfunction induced by mechanical ventilation &#x2013; pathophysiology and treatment options</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1352-8977</contrib-id><name><surname>Pa&#x017E;ur</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kova&#x010D;i&#x0107;</surname><given-names>Josipa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>O&#x017E;egi&#x0107;</surname><given-names>Ognjen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Zavod za anesteziologiju, intenzivnu medicinu i lije&#x010D;enje boli, Klini&#x010D;ki bolni&#x010D;ki centar Sestre milosrdnice</institution>, <addr-line>Zagreb</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Iva Pa&#x017E;ur, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-1352-8977">https://orcid.org/0000-0002-1352-8977</ext-link> Zavod za anesteziologiju, intenzivnu medicinu i lije&#x010D;enje boli, KBC Sestre milosrdnice, Vinogradska cesta 29, Zagreb, e-po&#x0161;ta: <email xlink:href="ivapr3@gmail.com">ivapr3@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>02</month><year>2022</year></pub-date>
<volume>144</volume>
<issue>1-2</issue>
<fpage>59</fpage>
<lpage>65</lpage>
<permissions>
<copyright-year>2022</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Disfunkcija o&#x0161;ita se javlja kod 60 &#x2013; 80% bolesnika koji su podvrgnuti mehani&#x010D;koj respiracijskoj potpori u jedinicama intenzivnog lije&#x010D;enja. Patofiziolo&#x0161;ki procesi koji dovode do disfunkcije toga najva&#x017E;nijeg respiracijskog mi&#x0161;i&#x0107;a zapo&#x010D;inju ve&#x0107; nakon 24 sata mehani&#x010D;ke ventilacije. Disfunkcija o&#x0161;ita zna&#x010D;ajno doprinosi ote&#x017E;anom odvajanju bolesnika od ventilatora, produljenju mehani&#x010D;ke ventilacije, pove&#x0107;anju morbiditeta i mortaliteta bolesnika. Etiologija disfunkcije o&#x0161;ita uzrokovane mehani&#x010D;kom ventilacijom (engl. <italic>ventilator induced diaphragm dysfunction</italic> &#x2013; VIDD) slo&#x017E;ena je i ovisna o vi&#x0161;e &#x010D;imbenika, uklju&#x010D;uje neuskla&#x0111;enost disanja izme&#x0111;u bolesnika i ventilatora, vi&#x0161;ednevnu vazopresornu potporu, ali i metaboli&#x010D;ke i upalne promjene u mi&#x0161;i&#x0107;nom tkivu kod kriti&#x010D;no oboljelih. Uz lije&#x010D;enje osnovnog uzroka zatajenja disanja, temelj uspje&#x0161;ne prevencije i lije&#x010D;enja VIDD-a predstavlja pravilno titriranje sedativa i mi&#x0161;i&#x0107;nih relaksansa, pra&#x0107;enje udjela spontane respiracijske aktivnosti, odabir proporcionalnih modaliteta ventilacije &#x010D;ija potpora spontanom disanju u odnosu na konvencionalne modalitete nije konstantna, ve&#x0107; je propocionalna spontanoj respiracijskoj aktivnosti. S ciljem prikaza najnovijih spoznaja iz podru&#x010D;ja patofiziologije i lije&#x010D;enja VIDD-a stru&#x010D;noj javnosti, elektroni&#x010D;ki su pretra&#x017E;ivane baze podataka <italic>PubMed, Medline</italic> i <italic>Google Scholar</italic>. Na&#x0161;e pretra&#x017E;ivanje je bilo ograni&#x010D;eno na randomizirana klini&#x010D;ka istra&#x017E;ivanja i na pregledne radove na engleskom jeziku koji su uklju&#x010D;ivali bolesnike starije od 18 godina, a koji su bili publicirani u razdoblju od 2016. do 2021., kori&#x0161;tenjem rje&#x010D;nika MeSH (engl. <italic>medical subject headings</italic>). <italic>Zaklju&#x010D;ak:</italic> Pandemija virusa SARS-CoV2 posebno je aktualizirala tematiku mehani&#x010D;ke ventilacije kao <italic>&#x201E;life saving&#x201C;</italic> metode lije&#x010D;enja koja mo&#x017E;e uzrokovati i zna&#x010D;ajne nuspojave poput disfunkcije o&#x0161;ita. Neprestano se razvijaju i usavr&#x0161;avaju nove strategije i modaliteti mehani&#x010D;ke ventilacije s ciljem za&#x0161;tite plu&#x0107;a, ali i o&#x0161;ita. Provo&#x0111;enjem mehani&#x010D;ke ventilacije s ciljem za&#x0161;tite o&#x0161;ita smanjuju se vrijeme trajanja mehani&#x010D;ke ventilacije, incidencija komplikacija poput vi&#x0161;estrukoga organskog zatajenja te posljedi&#x010D;no i mortalitet.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Majority of mechanically ventilated patients in intensive care units (ICU) suffer from diaphragm dysfunction. It occurs in approximately 60 to 80% of such patients. Early after the initiation of mechanical ventilation pathophysiological processes leading to diaphragm dysfunction are triggered. Inadequate diaphragm function significantly contributes to difficult weaning, prolonged mechanical ventilation as well as increased morbidity and mortality. Etiology of ventilation induced diaphragm dysfunction (VIDD) is complex and multifactorial. Metabolic and inflammatory changes in muscular tissue are one of the hallmarks of critical illness and together with patient-ventilator asynchrony and prolonged vasopressor support play a key role in VIDD pathophysiology. Treatment of primary cause of respiratory insufficiency is of utmost importance, but besides this, adequate titration of sedatives and muscle relaxants, monitoring of respiratory mechanics and deployment of proportional modes of ventilation are of great significance in prevention and treatment of VIDD. Proportional modes offer support to spontaneous breathing. However, unlike the conventional modes, this support is not constant, it changes with every breath, offering assistance that is proportional to activity of respiratory muscles. The aim of this article was to offer an insight into latest data from scientific literature to healthcare providers. The electronic search of Pubmed, Medline and Google Scholar was conducted by using MeSH (Medical Subject Headings) terms. Our search was limited to randomized controlled trials and review articles written in English, which were published from 2016 to 2021 and conducted on adult patients. <italic>Conclusion:</italic> During the pandemic of SARS-CoV-2, the importance of mechanical ventilation with all its aspects came into the focus of medical community. Mechanical ventilation is considered as a life saving method of treatment, but serious adverse effects such as dysfunction of diaphragm can be encountered. There are ongoing developments of new strategies and modes of mechanical ventilation aiming at protection of lungs and diaphragm. Diaphragm protective mechanical ventilation reduces the duration of mechanical ventilator support, decreases the incidence of severe complications such as multiple organ failure and consequntely mortality.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori O&#x0160;IT &#x2013; patofiziologija</kwd><kwd>MI&#x0160;I&#x0106;NA ATROFIJA &#x2013; etiologija, patofiziologija</kwd><kwd>MI&#x0160;I&#x0106;NA SLABOST &#x2013; etiologija, patofiziologija</kwd><kwd>MEHANI&#x010C;KA VENTILACIJA &#x2013; metode, ne&#x017E;eljeni u&#x010D;inci</kwd><kwd>HIPNOTICI I SEDATIVI &#x2013; terapijska uporaba</kwd><kwd>NEUROMI&#x0160;I&#x0106;NI BLOKATORI &#x2013; terapijska uporaba</kwd><kwd>ODVAJANJE OD VENTILATORA</kwd><kwd>INTERAKTIVNA POTPORA VENTILACIJI</kwd><kwd>RESPIRATORNI DISTRES SINDROM &#x2013; lije&#x010D;enje</kwd><kwd>INTENZIVNO LIJE&#x010C;ENJE</kwd><kwd>COVID-19</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>DIAPHRAGM &#x2013; physiopathology</kwd><kwd>MUSCULAR ATROPHY &#x2013; etiology, physiopathologhy</kwd><kwd>MUSCLE WEAKNESS &#x2013; etiology, physiopathologhy</kwd><kwd>RESPIRATION, ARTIFICIAL &#x2013; adverse effects, methods</kwd><kwd>HYPNOTICS AND SEDATIVES &#x2013; therapeutic use</kwd><kwd>NEUROMUSCULAR BLOCKING AGENTS &#x2013; therapeutic use</kwd><kwd>VENTILATOR WEANING</kwd><kwd>INTERACTIVE VENTILATORY SUPPORT</kwd><kwd>RESPIRATORY DISTRESS SYNDROME &#x2013; therapy</kwd><kwd>CRITICAL CARE</kwd><kwd>COVID-19</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>U jedinicama intenzivnog lije&#x010D;enja bolesnici mogu biti intubirani i mehani&#x010D;ki ventilirani zbog respiracijske insuficijencije razli&#x010D;ite etiologije. U ranijim publikacijama prepoznato je da osim korisnih u&#x010D;inaka za ljudski organizam mehani&#x010D;ka ventilacija mo&#x017E;e imati neke izrazito &#x0161;tetne u&#x010D;inke kako na plu&#x0107;a tako i na &#x010D;itav organizam pa su opisane komplikacije poput volutraume, barotraume, atelektotraume i biotraume. Navedena o&#x0161;te&#x0107;enja plu&#x0107;a mogu potaknuti poja&#x010D;ano osloba&#x0111;anje citokina s posljedi&#x010D;nim razvojem vi&#x0161;estruke organske disfunkcije i zatajenja (engl. <italic>multiple organ failure</italic> &#x2013; MOF). S vremenom je uo&#x010D;eno da osim plu&#x0107;a i o&#x0161;it treba za&#x0161;titi od ne&#x017E;eljenih posljedica mehani&#x010D;ke potpore di&#x0161;nom sustavu. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)</p>
<p>Ventilatorom inducirana disfunkcija o&#x0161;ita (engl. <italic>ventilator induced diaphragm disfunction</italic> &#x2013; VIDD) predstavlja specifi&#x010D;an oblik miotraume u subpopulaciji bolesnika na intenzivnom lije&#x010D;enju. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) VIDD se definira kao promjena u strukturi i kontraktilnoj funkciji o&#x0161;ita koja je uzrokovana mehani&#x010D;kom ventilacijom. Atrofija, ozljeda i slabost dijafragme mogu se javiti ve&#x0107; unutar 24 &#x2013; 48 sati od zapo&#x010D;injanja mehani&#x010D;ke ventilacije, a opseg ozljede o&#x0161;ita korelira s duljinom trajanja mehani&#x010D;ke ventilacije. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>&#x2013;<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) VIDD smatramo jednim od glavnih &#x010D;imbenika ote&#x017E;anog odvajanja od strojne respiratorne potpore (engl. <italic>weaninig</italic>) koji zna&#x010D;ajno utje&#x010D;e na trajanje mehani&#x010D;ke ventilacije, neuspje&#x0161;nost odvajanja od ventilatora te na mortalitet tih bolesnika. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) S obzirom na velik klini&#x010D;ki zna&#x010D;aj uz prevalenciju ovog poreme&#x0107;aja, cilj ovoga rada bio je napraviti pregled novijih znanstvenih i stru&#x010D;nih &#x010D;lanaka koji obra&#x0111;uju problem disfunkcije dijafragme uzrokovane mehani&#x010D;kom ventilacijom, a s naglaskom na patofiziologiju dijafragmalne disfunkcije te dana&#x0161;nje spoznaje o preventivnim i terapijskim mogu&#x0107;nostima.</p>
<p>Za potrebe ovoga rada elektroni&#x010D;ki su pretra&#x017E;ivane baze podataka <italic>PubMed</italic>, <italic>Medline</italic> i <italic>Google Scholar</italic>. Na&#x0161;e pretra&#x017E;ivanje je bilo ograni&#x010D;eno na randomizirana klini&#x010D;ka istra&#x017E;ivanja i na pregledne radove na engleskom jeziku koji su uklju&#x010D;ivali bolesnike starije od 18 godina, a koji su bili publicirani u razdoblju od 2016. do 2021., kori&#x0161;tenjem klju&#x010D;nih rije&#x010D;i MeSH (engl. <italic>medical subject headings</italic>).</p>
<sec sec-type="other1">
<title>Anatomija o&#x0161;ita</title>
<p>O&#x0161;it je najva&#x017E;niji respiratorni mi&#x0161;i&#x0107;. Odlikuje ga specifi&#x010D;an kupolast oblik &#x010D;ije mi&#x0161;i&#x0107;ne niti prema sredini prelaze u tetivne niti oblikuju&#x0107;i tetivno sredi&#x0161;te. Kontrakcijom mi&#x0161;i&#x0107;nih niti o&#x0161;ita spu&#x0161;ta se tetivno sredi&#x0161;te stvaraju&#x0107;i gradijent tlaka izme&#x0111;u atmosfere i alveola u plu&#x0107;ima omogu&#x0107;avaju&#x0107;i protok zraka u smjeru plu&#x0107;a i posljedi&#x010D;no &#x0161;irenje plu&#x0107;nog tkiva tijekom udisaja. Osjetnu i motori&#x010D;ku inervaciju o&#x0161;it dobiva od freni&#x010D;nog &#x017E;ivca.</p>
</sec>
<sec sec-type="other2">
<title>Epidemiologija VIDD-a</title>
<p>U populaciji bolesnika u jedinicama intenzivnog lije&#x010D;enja kod kojih je potrebna intubacija i mehani&#x010D;ka ventilacija, prevalencija dijafragmalne disfunkcije prema&#x0161;uje 60% i mo&#x017E;e dose&#x0107;i i 80% (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) u nekim slu&#x010D;ajevima ote&#x017E;anog odvajanja od respiratora. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Kako bi se predvidjelo koji &#x0107;e se bolesnici uspje&#x0161;no odvojiti od ventilatora provodi se poku&#x0161;aj spontanog disanja (engl. <italic>spontaneous breathing trial</italic> &#x2013; SBT). Ote&#x017E;anim odvajanjem bolesnika od strojne ventilacije smatra se postizanje odvajanja nakon provedena do tri SBT-a, odnosno odvajanje unutar 7 dana od prvog SBT-a. Produljeno odvajanje bolesnika od strojne ventilacije odnosi se na tri ili vi&#x0161;e neuspje&#x0161;nih SBT-a ili odvajanje dulje od 7 dana nakon inicijalnog SBT-a. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Neuspje&#x0161;na ekstubacija stoji u korelaciji s progresivnim pove&#x0107;anjem mortaliteta &#x2013; od 19% kod bolesnika koji su dan nakon prvog poku&#x0161;aja odvajanja od respiratora i dalje mehani&#x010D;ki ventilirani do njih 37% nakon 10 dana. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Patofiziologija disfunkcije o&#x0161;ita uzrokovane mehani&#x010D;kom ventilacijom</title>
<p>Patofiziologija VIDD-a je slo&#x017E;ena kao i op&#x0107;enit pojam miopatije kod kriti&#x010D;ne bolesti (engl. <italic>critical illness myopathy</italic> &#x2013; CIM). CIM naj&#x010D;e&#x0161;&#x0107;e zahva&#x0107;a respiracijske mi&#x0161;i&#x0107;e i proksimalne mi&#x0161;i&#x0107;ne skupine ekstremiteta, dok su mi&#x0161;i&#x0107;i koji dobivaju inervaciju od kranijalnih &#x017E;ivaca uglavnom po&#x0161;te&#x0111;eni. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Incidencija CIM-a u jedinicama intenzivnog lije&#x010D;enja kre&#x0107;e se od 25% do 83%, ovisno o uzro&#x010D;noj kriti&#x010D;noj bolesti. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) U ve&#x0107;ini slu&#x010D;ajeva CIM ostaje neprepoznat dok ne nastupi nemogu&#x0107;nost odvajanja bolesnika od mehani&#x010D;ke respiratorne potpore. Patofiziologija CIM-a nije u potpunosti razja&#x0161;njena. Prema recentnoj literaturi smatra se da uklju&#x010D;uje promjene u metabolizmu miocita, elektrofiziologiji i mikrovaskulaturi mi&#x0161;i&#x0107;a. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>, <xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) U sklopu sistemnoga upalnog odgovora kakav se odvija primjerice u sepsi, pokre&#x0107;e se i upalni odgovor u mi&#x0161;i&#x0107;ima. Osloba&#x0111;aju se slobodni radikali kisika (engl. <italic>reactive oxygen species</italic> &#x2013; ROS) iz neutrofila, a aktivacijom transkipcijskog faktora NF kappa b (<italic>nuclear factor kappa b</italic>) sintetiziraju se proinflamatorni citokini (TNF alfa, IL6, IL1), koji na razini mitohondrija inhibiraju piruvat dehidrogenazu i aerobni metabolizam. Uslijed nedostatnih koli&#x010D;ina ATP-a (adenozin trifosfat) nastaje stani&#x010D;ni energetski deficit. Mitohondriji su poznati kao glavni izvor ROS-a. U bioptatima o&#x0161;ita, na animalnim modelima, na&#x0111;ene su pove&#x0107;ane razine superoksid dismutaze, markera oksidativnog stresa. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Energetskom deficitu doprinosi i deficit glukoze kao energetskog supstrata. Jedan od pretpostavljenih mehanizama CIM-a je i nedostatna opskrba mi&#x0161;i&#x0107;a glukozom zbog izostanka translokacije GLUT4 (<italic>glucose transporter 4</italic>) na sarkolemalnu membranu. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Tako&#x0111;er, sekvencioniranjem RNA kod CIM-bolesnika na&#x0111;ena je promijenjena ekspresija gena koji su uklju&#x010D;eni u proces kontrakcije mi&#x0161;i&#x0107;a. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Atrofiji mi&#x0161;i&#x0107;a doprinosi i neuropatija kriti&#x010D;ne bolesti (engl. <italic>critical illness neuropathy</italic> &#x2013; CIN) koja s degeneracijom aksona i inaktivacijom natrijevih kanala dovodi do smanjene podra&#x017E;ljivosti perifernih &#x017E;ivaca i njihove disfunkcije. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Osim promjena na aksonima, poreme&#x0107;ena je i regulacija ekscitabilnosti mi&#x0161;i&#x0107;ne membrane tijekom kriti&#x010D;ne bolesti uslijed inaktivacije ionskih natrijskih kanala na mi&#x0161;i&#x0107;noj stani&#x010D;noj membrani, ote&#x017E;anog stvaranja akcijskog potencijala i mi&#x0161;i&#x0107;ne kontrakcije. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>)</p>
<p>Na razini mikrovaskulature, slobodni radikali kisika i proupalni citokini o&#x0161;te&#x0107;uju kapilarni endotel doprinose&#x0107;i edemu zahva&#x0107;enog tkiva, aktivaciji koagulacije i nastajanju mikrotromba. Posljedi&#x010D;no dolazi do sloma mikrocirkulacije i insuficijentne perfuzije mi&#x0161;i&#x0107;a. Disregulacija upalnog procesa dovodi, na razini mi&#x0161;i&#x0107;a, do atrofije i gubitka kontraktilne funkcije miofibrila te do smanjenja snage mi&#x0161;i&#x0107;ne kontrakcije. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) Zbog svega navedenog razvijaju se mi&#x0161;i&#x0107;ni umor i slabost. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>, <xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Imobilizacija, upala i visoka &#x017E;ivotna dob doprinose ranije navedenim procesima. Sve navedeno utje&#x010D;e na mi&#x0161;i&#x0107;e tijela u cjelini, a u slu&#x010D;aju o&#x0161;ita mehani&#x010D;ka ventilacija mo&#x017E;e predstavljati dodatnu noksu.</p>
</sec>
<sec sec-type="other4">
<title>Uloga farmakoterapije u jedinici intenzivnog lije&#x010D;enja na razvoj VIDD-a</title>
<sec>
<title>Analgetici, sedativi i mi&#x0161;i&#x0107;ni relaksansi</title>
<p>Analgetici i sedativi su sastavni dio terapije bolesnika u jedinicama intenzivnog lije&#x010D;enja. Kod bolesnika koji zahtijevaju invazivni oblik mehani&#x010D;ke respiracijske potpore, odnosno endotrahealnu intubaciju i mehani&#x010D;ku ventilaciju, propisujemo ih s ciljem smanjivanja boli, napetosti i neugode prilikom zbrinjavanja di&#x0161;nog puta, same mehani&#x010D;ke ventilacije, ali i radi kupiranja boli uslijed razli&#x010D;itih invazivnih postupka koji su dio dijagnostike i lije&#x010D;enja bolesnika u JIL-u. Tako&#x0111;er, analgetici i sedativi olak&#x0161;avaju interakciju bolesnik &#x2013; ventilator smanjuju&#x0107;i njihovu neuskla&#x0111;enost te na taj na&#x010D;in djeluju protektivno na plu&#x0107;ni parenhim i o&#x0161;ita. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Pretjerana spontana respiracijska aktivnost bolesnika mo&#x017E;e dovesti do samonano&#x0161;enja ozljede plu&#x0107;a (engl. <italic>patient self inflicted lung injury</italic> &#x2013; P-SILI). Spontano disanje generira negativni intrapleuralni tlak koji udru&#x017E;en s pozitivim tlakom u di&#x0161;nom putu od strane ventilatora pove&#x0107;ava transpulmonalni tlak koji rezultira velikim respiracijskim volumenom, vazodilatacijom i plu&#x0107;nim edemom. U tom kontekstu supresija spontanog disanja analgeticima i sedativima za&#x0161;ti&#x0107;uje plu&#x0107;ni parenhim.</p>
<p>Opioidi su temelj lije&#x010D;enja boli tijekom mehani&#x010D;ke ventilacije, a najzastupljeniji su jaki opioidi poput morfija, fentanila ili sufentanila. Primjena remifentanila, kao relativno novog opioida, povezuje se s kra&#x0107;im trajanjem mehani&#x010D;ke ventilacije i boravka u JIL-u u odnosu na druge opioide. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>)</p>
<p>U klini&#x010D;koj praksi naj&#x010D;e&#x0161;&#x0107;e kori&#x0161;teni lijekovi koji djeluju kao sedativi ili hipnotici, ovisno o dozi, jesu benzodiazepini, propofol i deksmedetomidin.</p>
<p>Benzodiazepini se povezuju s pove&#x0107;anom incidencijom delirija, predubokom sedacijom i produ&#x017E;enim odvajanjem bolesnika od respiratora.</p>
<p>Propofol mo&#x017E;e izazvati propofolski infuzijski sindrom (engl. <italic>propofol infusion syndrome</italic> &#x2013; PRIS) s mogu&#x0107;im fatalnim posljedicama. Stoga se njegova primjena kao sedativa u kontinuiranoj infuziji izbjegava.</p>
<p>Deksmedetomidin, kao relativno novije primjenjivani sedativ, za razliku od prethodno spomenutih lijekova ne izaziva depresiju disanja i ima analgetski u&#x010D;inak. Agitiranost bolesnika i delirij &#x010D;esti su kod bolesnika koji su mehani&#x010D;ki ventilirani i doprinose ote&#x017E;anom odvajanju od ventilatora. Deksmedetomidin smanjuje rizik nastanka delirija. Povezuje se s br&#x017E;im odvajanjem od ventilatora i kra&#x0107;im boravkom na intenzivnoj skrbi, ali bez u&#x010D;inka na mortalitet i trajanje delirija kod bolesnika u JIL-u. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Od nuspojava najizra&#x017E;enije su hipotenzija i bradikardija.</p>
<p>U slu&#x010D;aju te&#x0161;kog oblika ARDS-a (engl. <italic>adult respiratory distress syndrome</italic>), uz potrebu za postavljanjem bolesnika u potrbu&#x0161;ni polo&#x017E;aj (engl. <italic>prone position</italic>), asinkroniju i jako izra&#x017E;en poticaj disanju (engl. <italic>respiratory drive</italic>), u terapiju se uz analgosedaciju uvode i mi&#x0161;i&#x0107;ni relaksansi u kontinuiranoj infuziji kroz 24 do 48 sati. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Prema kemijskoj strukturi mi&#x0161;i&#x0107;ni relaksansi pripadaju benzoizokinolinskoj (atrakurij, cisatrakurij, mivakurij) ili aminosteroidnoj skupini (rokuronij, vekuronij). Primjena mi&#x0161;i&#x0107;nih relaksansa u JIL-u dovodi do imobilizacije bolesnika i pove&#x0107;anog rizika od komplikacija poput mi&#x0161;i&#x0107;ne atrofije, ozljede perifernih &#x017E;ivaca, dekubitusa i razvoja duboke venske tromboze, kao i akcidentalne budnosti relaksiranog bolesnika uslijed plitke analgosedacije. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
<p>Preduboka analgosedacija je povezana s pove&#x0107;anom incidencijom delirija, produ&#x017E;enim odvajanjem bolesnika od strojne ventilacije i pove&#x0107;anim mortalitetom. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Osim &#x0161;to doprinosi atrofiji o&#x0161;ita i produ&#x017E;enom odvajanju od respiratora, analgosedacija mo&#x017E;e izazvati ili pogor&#x0161;ati hemodinamsku nestabilnost bolesnika zahtijevaju&#x0107;i uvo&#x0111;enje vazopresora u terapiju.</p>
<p>Stoga je analgosedaciju i mi&#x0161;i&#x0107;nu relaksaciju potrebno pa&#x017E;ljivo titrirati, redovito procjenjuju&#x0107;i klini&#x010D;ki status bolesnika, laboratorijske nalaze i postavke ventilatora kako bi se njihova primjena ograni&#x010D;ila na &#x0161;to je mogu&#x0107;e kra&#x0107;i period.</p>
<p>Zaklju&#x010D;no, potrebno je posti&#x0107;i balans izme&#x0111;u preduboke sedacije i pretjerane spontane respiracijske aktivnosti tijekom mehani&#x010D;ke ventilacije koja mo&#x017E;e potencirati ozljedu plu&#x0107;a i o&#x0161;ita.</p>
</sec>
<sec>
<title>Vazoaktivni lijekovi</title>
<p>Rezultati randomiziranoga klini&#x010D;kog istra&#x017E;ivanja autora Wolfe, et al. ukazuju da uporaba vazoaktivnih lijekova predstavlja rizi&#x010D;an faktor, neovisno o postojanju ranije utvr&#x0111;enih &#x010D;imbenika rizika za razvoj mi&#x0161;i&#x0107;ne slabosti bolesnika na intenzivnom lije&#x010D;enju. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Trajanje medikamentozne vazoaktivne potpore i ukupna dnevna doza noradrenalina neovisni su predvi&#x0111;aju&#x0107;i &#x010D;imbenici za pojavu mi&#x0161;i&#x0107;ne slabosti bolesnika na intenzivnom lije&#x010D;enju. Za svaki mikrogram noradrenalina po kilogramu tjelesne mase koji bolesnik dnevno primi rizik od razvoja mi&#x0161;i&#x0107;ne slabosti pove&#x0107;ava se za 1%. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Na podru&#x010D;ju kardiovaskularnih lijekova s potencijalnim pozitivnim djelovanjem na funkciju mi&#x0161;i&#x0107;a istra&#x017E;ivanja s levosimendanom pokazala su njegovu mogu&#x0107;u povoljnu ulogu u oporavku mi&#x0161;i&#x0107;ne funkcije. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Levosimendan se kao inodilatator primarno koristi kod akutnoga sr&#x010D;anog zatajenja. Pove&#x0107;ava osjetljivost troponina C na kalcij, te tako pove&#x0107;ava kontraktilnost tijekom sistole bez dodatnog optere&#x0107;enja stanice kalcijem i bez dodatne potro&#x0161;nje kisika. Zasad je provedeno pilot-istra&#x017E;ivanje na 19 bolesnika s ejekcijskom frakcijom lijevog ventikula (LVEF) od 34 &#x00B1; 8%, od kojih se 8 odvojilo od ventilatora nakon prvog SBT-a. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Kod preostalih 11 bolesnika provedeno je lije&#x010D;enje levosimendanom. Tijekom drugog SBT-a zabilje&#x017E;en je porast parcijalnog tlaka kisika (93 &#x00B1; 34 <italic>vs.</italic> 67 &#x00B1; 28 mm Hg, <italic>p</italic>=0,03) i saturacije centralne venske krvi (66 &#x00B1; 11% <italic>vs.</italic> 57 &#x00B1; 9%, <italic>p</italic>=0,02) u odnosu na prvi SBT. U 9 od 11 ispitanika koji su lije&#x010D;eni levosimendanom provedeno je uspje&#x0161;no odvajanje od mehani&#x010D;ke ventilacije. Iako nije dokazana razlika u neuromehani&#x010D;koj funkciji o&#x0161;ita izme&#x0111;u skupine s levosimendanom i placebo skupine, zaklju&#x010D;eno je kako se pobolj&#x0161;anjem sistoli&#x010D;ke i dijastoli&#x010D;ke funkcije srca omogu&#x0107;ava i br&#x017E;e odvajanje od ventilatora. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Naravno, potrebna su daljnja istra&#x017E;ivanja na ve&#x0107;em uzorku ispitanika.</p>
</sec>
<sec>
<title>Metilksantini</title>
<p>S metilksantinima (teofilin i aminofilin) kao bronhodilatatorima postoje dugogodi&#x0161;nja iskustva u klini&#x010D;koj praksi u lije&#x010D;enju bolesnika s astmom i kroni&#x010D;nom opstruktivnom plu&#x0107;nom bolesti (KOPB). Osim bronhodilatacijskog u&#x010D;inka teofilin stimulira mre&#x017E;u neurona u respiracijskom centru, pove&#x0107;ava aktivnost respiracijskih mi&#x0161;i&#x0107;a uklju&#x010D;uju&#x0107;i i o&#x0161;it, me&#x0111;urebrene mi&#x0161;i&#x0107;e, kao i popre&#x010D;ni abdominalni mi&#x0161;i&#x0107;. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Osim poznatog mehanizma djelovanja kao inhibitor fosfodiesteraze, va&#x017E;no je istaknuti da se teofilin odlikuje antiinflamatornim i antinociceptivnim u&#x010D;inkom. Inhibira NFkB (engl. <italic>nuclear factor kappa beta</italic>), transkripcijski faktor za proinflamatorne citokine i poja&#x010D;ava aktivnost IL-10 (interleukin 10) koji djeluje protuupalno. Kim, et al. su u istra&#x017E;ivanju provedenom na 40 ispitanika dokazali kako teofilin zna&#x010D;ajno pove&#x0107;ava pokretljivost o&#x0161;ita kod bolesnika s VIDD-om. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Me&#x0111;utim, isto nije uo&#x010D;eno kod bolesnika kojima nije dijagnosticiran VIDD. Od 40 ispitanika koji su bili uklju&#x010D;eni u istra&#x017E;ivanje, 21 ih je primilo teofilin u dozi od 200 mg dnevno. U teofilinskoj skupini zabilje&#x017E;ene su zna&#x010D;ajno ve&#x0107;e ekskurzije o&#x0161;ita u odnosu na kontrolnu skupinu (6,9 &#x00B1; 9,1 mm <italic>vs</italic> 0,5 &#x00B1; 5,7 mm, p = 0,02). Procjena ekskurzija o&#x0161;ita obostrano provedena je uz pomo&#x0107; ultrazvuka. Ultrazvu&#x010D;na sonda se postavlja u razini donjih rebara u sredi&#x0161;njoj aksilarnoj liniji s lijeve i desne strane, &#x010D;ime se prika&#x017E;e stra&#x017E;nje podru&#x010D;je o&#x0161;ita obostrano. Tijekom udisaja kontrakcije o&#x0161;ita se bilje&#x017E;e u ultrazvu&#x010D;nom M-modu, a amplituda ekskurzija se mjeri u vertikalnoj osi od osnovne linije do najvi&#x0161;e to&#x010D;ke amplitude u udisaju. Ultrazvu&#x010D;no se VIDD dijagnosticira kad su ekskurzije o&#x0161;ita manje od 10 mm ili ih nema. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>, <xref ref-type="bibr" rid="r29"><italic>29</italic></xref>)</p>
</sec>
<sec>
<title>Posljedice interakcije bolesnika i ventilatora</title>
<p>Tijekom mehani&#x010D;ke ventilacije bolesnika na intenzivnoj skrbi dolazi do interakcije ure&#x0111;aja za mehani&#x010D;ku ventilaciju i ljudskog organizma. S obzirom na to da kod bolesnika u JIL-u uglavnom postoje spontani poku&#x0161;aji disanja, za nadle&#x017E;nog klini&#x010D;ara predstavlja izazov pravodobno pratiti promjene u mehanici disanja i na adekvatan na&#x010D;in mijenjati postavke ventilatora kako bi se izbjegla neuskla&#x0111;enost ure&#x0111;aja i bolesnika. Op&#x0107;enito, jedan od ciljeva mehani&#x010D;ke ventilacije kod bolesnika jest smanjenje rada disanja (engl. <italic>work of breathing</italic> &#x2013; WoB) kako ne bi do&#x0161;lo do nepotrebne potro&#x0161;nje kisika i optere&#x0107;enja kardiovaskularnog sustava &#x010D;ija je rezerva ionako kompromitirana kod mnogih bolesnika u JIL-u. U normalnim okolnostima na perfuziju respiracijskih mi&#x0161;i&#x0107;a odlazi oko 2% sr&#x010D;anoga minutnog volumena, dok kod respiracijske insuficijencije taj udio raste i do 40%. S druge strane, nastoji se ograni&#x010D;iti pretjerana mehani&#x010D;ka potpora koja dovodi do atrofije o&#x0161;ita i njezine disfunkcije. Tako&#x0111;er, pretjerano optere&#x0107;enje o&#x0161;ita koje dovodi do hipertrofije mi&#x0161;i&#x0107;a ima negativan u&#x010D;inak na odvajanje od mehani&#x010D;ke ventilacije. Ovdje razlikujemo koncentri&#x010D;ni i ekscentri&#x010D;ni tip optere&#x0107;enja. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Koncentri&#x010D;ni tip mogu uzrokovati pove&#x0107;an rad disanja tijekom udisaja, nedostatna tla&#x010D;na potpora disanju tijekom mehani&#x010D;ke ventilacije i neuskla&#x0111;enost ventilatora i bolesnika. U slu&#x010D;aju premalog PEEP-a (engl. <italic>positive end-expiratory pressure</italic>), prevelikog smanjenja volumena plu&#x0107;a na kraju ekspirija i prisutnosti neuskla&#x0111;enosti izme&#x0111;u bolesnika i ventilatora, razvija se ekscentri&#x010D;no optere&#x0107;enje koje predstavlja ve&#x0107;i rizik za razvoj VIDD-a. Ekscentri&#x010D;no optere&#x0107;enje nastaje uslijed kontrakcije mi&#x0161;i&#x0107;nih vlakana o&#x0161;ita tijekom izdisaja, kada bi fiziolo&#x0161;ki trebalo do&#x0107;i do njihovog produljenja, sa svrhom prevencije atelektaza i odr&#x017E;avanja plu&#x0107;nog volumena. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Dakle, kod ekscentri&#x010D;nog optere&#x0107;enja, za razliku od koncentri&#x010D;nog, o&#x0161;it je aktivan tijekom izdisaja. Do opisanog slu&#x010D;aja dolazi kada zadano vrijeme trajanja udisaja i izdisaja nije uskla&#x0111;eno s duljinom trajanja bolesnikovog udisaja, &#x0161;to je centralno determinirano, odnosno kontrolirano neuronima u centru za disanje na temelju ulaznih signala s periferije. U oba slu&#x010D;aja dolazi do ozljede mi&#x0161;i&#x0107;a i mi&#x0161;i&#x0107;ne slabosti, kao i u slu&#x010D;aju prekomjerne mehani&#x010D;ke potpore disanju. Dakle, potrebno je posti&#x0107;i ravnote&#x017E;u izme&#x0111;u mehani&#x010D;ke asistencije di&#x0161;nim mi&#x0161;i&#x0107;ima i njihove spontane aktivnosti koja sama po sebi &#x010D;esto nije dovoljna da bi se ostvarila adekvatna izmjena kisika i uglji&#x010D;nog dioksida. Prevaga na jednu ili drugu stranu dovodi do disfunkcije o&#x0161;ita, odnosno miopatije koja rezultira ote&#x017E;anim odvajanjem bolesnika od mehani&#x010D;ke ventilacije, &#x0161;to u kona&#x010D;nici ima negativan efekt na ishod lije&#x010D;enja. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>)</p>
<p>Neadekvatna mehani&#x010D;ka potpora respiraciji, osim na di&#x0161;ni sustav, ima i neposredne posljedice na funkciju kardiovaskularnog sustava. Pove&#x0107;ani intratorakalni tlak name&#x0107;e tla&#x010D;no optere&#x0107;enje desnom srcu pove&#x0107;avaju&#x0107;i plu&#x0107;nu vaskularnu rezistenciju, a istodobno smanjuje priljev krvi u desno srce kompromitiraju&#x0107;i tako njegovu funkciju i smanjuju&#x0107;i sr&#x010D;ani minutni volumen sa svim posljedicama koje ono ima na organizam u cjelini. Efekt na lijevo srce je obrnut, smanjeno je volumno i tla&#x010D;no optere&#x0107;enje pa je i funkcija lijevog srca pobolj&#x0161;ana. U slu&#x010D;aju prejakih spontanih poku&#x0161;aja disanja (uslijed premale tla&#x010D;ne potpore, neadekvatne sedacije) negativni tlak u intrapleuralnom prostoru koji stvara o&#x0161;it u kombinaciji s pozitivnim tlakom u di&#x0161;nom sustavu koji generira ventilator rezultiraju prevelikim di&#x0161;nim volumenima koji uzrokuju prekomjernu distenziju alveola i njihovo o&#x0161;te&#x0107;enje, ali imaju i negativan u&#x010D;inak na plu&#x0107;nu hemodinamiku. Uslijed negativnoga intrapleuralnog tlaka raste transmuralni vaskularni tlak (razlika izme&#x0111;u intravaskularnog i ekstramuralnog tlaka) te se posljedi&#x010D;no pove&#x0107;ava perfuzija kroz plu&#x0107;a koja mo&#x017E;e dovesti do plu&#x0107;nog edema i pogor&#x0161;anja respiracijske funcije. (<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>)</p>
<p>U poku&#x0161;aju da se nadvladaju spomenute zapreke i pobolj&#x0161;a sinkronizacija bolesnik &#x2013; ventilator razvijena je neuralno prilago&#x0111;ena ventilacijska pomo&#x0107; (engl. <italic>neurally adjusted ventilatory assisted</italic> &#x2013; NAVA), modalitet ventilacije koji spada u proporcionalne modalitete asistencije. Klju&#x010D;na razlika u odnosu na konvencionalne modalitete jest u tome da tla&#x010D;na potpora respiratora nije konstantna, ve&#x0107; je proporcionalna naporu (veli&#x010D;ini mi&#x0161;i&#x0107;ne kontrakcije) koji bolesnik izvr&#x0161;i prilikom udisaja i mijenja se kod svakog respiracijskog ciklusa. U modu NAVA koristi se nazogastri&#x010D;na sonda s mikroelektrodama na distalnom kraku koje bilje&#x017E;e elektri&#x010D;nu aktivnost o&#x0161;ita (EAdi). Putem transezofagealne elektromiografije ventilator asistira bolesniku tijekom udisaja na takav na&#x010D;in da je ta asistencija proporcionalna svakom milivoltu elektri&#x010D;ne aktivnosti o&#x0161;ita. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Smanjenjem EAdi-a na unaprijed zadan postotak prestaje i mehani&#x010D;ka potpora, pa imamo dobru uskla&#x0111;enost mehani&#x010D;ke asistencije s trajanjem bolesnikovog udaha, &#x010D;ime se izbjegava neuskla&#x0111;enost s ventilatorom i njezini &#x0161;tetni u&#x010D;inci na mehaniku disanja bolesnika. Istovremeno se posti&#x017E;e fiziolo&#x0161;ka asistencija o&#x0161;itu izbjegavaju&#x0107;i razvoj VIDD-a. Zaklju&#x010D;no, mehani&#x010D;ka tla&#x010D;na potpora u modalitetu NAVA tijekom inspirija nije ni prevelika ni premala, nego je proporcionalna bolesnikovom naporu.</p>
</sec>
</sec>
<sec sec-type="other5">
<title>Kako ispravno procijeniti ventiliramo li dobro bolesnika i je li je na&#x0161;a ventilacija protektivna za plu&#x0107;a i o&#x0161;it?</title>
<p>Klini&#x010D;ka inspekcija bolesnika mo&#x017E;e ve&#x0107; dati odgovor na ovo pitanje. Prisutnost paradoksalnog disanja kod kojega prilikom udaha dolazi do uvla&#x010D;enja abdominalne stijenke, a tijekom izdisaja do njezinog izbo&#x010D;enja, ukazuje na slabost o&#x0161;ita. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Ostali alati koji su klini&#x010D;aru na raspolaganju jesu odre&#x0111;ivanje mehani&#x010D;kog indeksa respiratornog pogona u inspiriju P<sub>0,1</sub>. Valvula se na inspiratornom kraku ventilatora zatvori na 100 ms, sprje&#x010D;avaju&#x0107;i protok smjese plinova prema bolesniku. Dobivena vrijednost na monitoru P<sub>0,1</sub> pokazuje nam koliko je sna&#x017E;an poticaj za disanje (engl. <italic>respiratory drive</italic>) (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>), odnosno je li optere&#x0107;enost o&#x0161;ita premala ili prevelika. Optimalna vrijednost P<sub>0,1</sub> je izme&#x0111;u 1,5 i 3,5 mbar. Vrijednosti defleksije tlaka u di&#x0161;nom putu (Paw) manje od 1,5 mbara, dok je inspiratorna valvula zatvorena, ukazuju na preslabu aktivnost o&#x0161;ita, a vrijednosti ve&#x0107;e od 5 mbara prisutne su kod prejakoga respiratornog poticaja, odnosno kod prejake spontane aktivnosti koja mo&#x017E;e trigerirati niz ranije navedenih &#x0161;tetnih u&#x010D;inaka na respiraciju i hemodinamiku. Ezofagealni tlak je surogat pleuralnog tlaka pa manometrija ezofagealnim balonom daje korisne podatke o vrijednostima pleuralnog tlaka iz kojih se poznavaju&#x0107;i tlak u di&#x0161;nom sustavu (Paw) mo&#x017E;e izra&#x010D;unati transpulmonalni tlak (Ptp), odnosno tlak koji je odgovoran za distenziju alveola. Preporuka je da se Ptp, koji je razlika tlaka u di&#x0161;nom sustavu i pleuralnog tlaka, odr&#x017E;ava na vrijednostima ispod 20 &#x2013; 25 mbar kako bi se izbjegla pretjerana distenzija alveola.</p>
</sec>
<sec sec-type="other6">
<title>COVID-19 i mehani&#x010D;ka ventilacija</title>
<p>S obzirom na aktualnost pandemije SARS-CoV-2 i potrebu za mehani&#x010D;kom ventilacijom bolesnika oboljelih od COVID-19 od kojih neki razviju ARDS, odnosno kriti&#x010D;ni oblik bolesti, potrebno je osvrnuti se na problem mehani&#x010D;ke ventilacije u uvjetima navedene pandemije. Kod bolesnika s progresivnim razvojem hipoksemije, refraktorne na primjenu neinvazivnih oblika oksigenacije (maska s kisikom, visokoproto&#x010D;na nazalna oksigenacija i neinvazivna ventilacija), pristupa se endotrahealnoj intubaciji i mehani&#x010D;koj ventilaciji. Uz etiolo&#x0161;ko lije&#x010D;enje, mehani&#x010D;ka ventilacija predstavlja temelj lije&#x010D;enja ARDS-a. Tijekom proteklih desetlje&#x0107;a do&#x0161;lo je do zna&#x010D;ajnog napretka u razumijevanju patofiziologije ARDS-a i sukladno tomu i prilagodbe postavki mehani&#x010D;ke ventilacije koja je doprinijela smanjenju mortaliteta od ARDS-a. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>&#x2013;<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) Respiracijski volumeni se kre&#x0107;u od 4 do 6 ml/kg idealne tjelesne te&#x017E;ine, tlak platoa (P<sub>plat</sub>) trebao bi biti ispod 30 mbara, uz kori&#x0161;tenje PEEP-a od minimalno 5 mbar. U slu&#x010D;aju ARDS-a izazvanog virusom SARS-CoV-2 slijede se ranije utvr&#x0111;eni protokoli protektivne plu&#x0107;ne ventilacije. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>) Pritom treba napomenuti kako kod infekcije virusom SARS-CoV-2 s razvojem ARDS-a postoje tri razli&#x010D;ita fenotipa. Prvi fenotip se odlikuje o&#x010D;uvanom popustljivo&#x0161;&#x0107;u plu&#x0107;a, malim brojem rekrutabilnih alveola i te&#x0161;kom hipoksemijom. Pove&#x0107;ana je perfuzija plu&#x0107;a te se razvija mimotok. U ovom slu&#x010D;aju treba primijeniti umjerene vrijednosti PEEP-a s ciljem redistribucije plu&#x0107;nog krvotoka prema bolje ventiliranim alveolama. U drugom tipu dominiraju atelektaze. Potrebne su umjerene do visoke vrijednosti PEEP-a i/ili postavljanje bolesnika u potrbu&#x0161;ni polo&#x017E;aj kako bi se otvorile alveole. Tre&#x0107;i tip fenotipa vi&#x0161;e nalikuje klasi&#x010D;nom ne-COVID-19 ARDS-u s niskom popustljivo&#x0161;&#x0107;u plu&#x0107;a i edemom alveola te se primjenjuju trenutno va&#x017E;e&#x0107;i protokoli za lije&#x010D;enje ARDS-a uz primjenu umjerenih do visokih vrijednosti PEEP-a. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>, <xref ref-type="bibr" rid="r38"><italic>38</italic></xref>)</p>
<p>Primjena potrbu&#x0161;nog polo&#x017E;aja (engl. <italic>prone position</italic>) tijekom aktualne pandemije pokazala se kao u&#x010D;inkovita, jeftina i relativno jednostavna metoda kojom se mo&#x017E;e pobolj&#x0161;ati oksigenacija bolesnika. Primjenjuje se kod te&#x0161;kog oblika ARDS-a (PaO2/FiO2&lt;150 mm Hg) te je va&#x017E;no po&#x010D;eti s potrbu&#x0161;nim polo&#x017E;ajem &#x0161;to ranije u tijeku bolesti ukoliko nema kontraindikacija i primjenjivati ga u ciklusima od 12 &#x2013; 18 sati dnevno u periodu od 3 &#x2013; 5 dana. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>, <xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Apsolutna kontraindikacija za primjenu potrbu&#x0161;nog polo&#x017E;aja jest nestabilan prijelom kralje&#x017E;nice, dok se povi&#x0161;en intrakranijalni tlak, hemodinamska nestabilnost, otvorena abdominalna rana, nestabilan prijelom zdjeli&#x010D;nih i dugih kostiju smatraju relativnim kontraindikacijama i potrebno ih je individualno razmotriti za svakog bolesnika. Potrbu&#x0161;ni polo&#x017E;aj se primjenjuje se kao &#x201E;<italic>rescue</italic>&#x201C; metoda lije&#x010D;enja kod refraktorne hipoksemije unato&#x010D; mehani&#x010D;koj ventilaciji s visokim udjelom kisika u inspiratornoj smjesi plinova (FiO2) i visokim vrijednostima PEEP-a. Naravno, nije u&#x010D;inkovit kod svih bolesnika. Smatra se kako u pronacijskom polo&#x017E;aju dolazi do pravilnije distribucije ventilacije i perfuzije te se rastere&#x0107;uje desno srce. Mo&#x017E;emo ga smatrati jednom vrstom <italic>recruitment</italic> manevra.</p>
</sec>
<sec sec-type="other7">
<title>Zaklju&#x010D;ak</title>
<p>Mehani&#x010D;ka ventilacija, poput svakoga dijagnosti&#x010D;kog ili terapijskog postupka, osim korisnih u&#x010D;inaka za ljudsko zdravlje ima i odre&#x0111;ene nuspojave koje nastojimo izbje&#x0107;i ili smanjiti njihov utjecaj. Pritom osim za&#x0161;tite plu&#x0107;a u fokus treba staviti i o&#x010D;uvanje funkcije respiracijskih mi&#x0161;i&#x0107;a, poglavito o&#x0161;ita. U dana&#x0161;njim izazovnim vremenima, s obzirom na pandemiju SARS-CoV-2, kontroverze oko najbolje mogu&#x0107;e strategije koju primjenjujemo u mehani&#x010D;koj ventilaciji bolesnika aktualnije su nego ikada. Za&#x0161;titom respiracijske muskulature smanjujemo vrijeme trajanja mehani&#x010D;ke ventilacije, smanjuje se incidencija komplikacija od kojih je najte&#x017E;e vi&#x0161;estruko organsko zatajenje, pobolj&#x0161;ava se ishod lije&#x010D;enja i smanjuje mortalitet. U kontekstu za&#x0161;tite o&#x0161;ita naglasak je na odr&#x017E;avanju adekvatne mehani&#x010D;ke potpore spontanom disanju, imaju&#x0107;i u vidu kako pretjerana spontana aktivnost respiracijskih mi&#x0161;i&#x0107;a mo&#x017E;e biti jednako rizi&#x010D;na za razvoj VIDD-a kao i potpuno odsutna ili preslaba aktivnost o&#x0161;ita.</p>
</sec>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Jonkman</surname><given-names>AH</given-names></name><name><surname>Dianti</surname><given-names>J</given-names></name><name><surname>Vaporidi</surname><given-names>K</given-names></name><name><surname>Beitler</surname><given-names>JR</given-names></name><name><surname>Patel</surname><given-names>BK</given-names></name><etal/></person-group> <article-title>Clinical strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient and excessive effort.</article-title> <source>Intensive Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>12</issue>):<fpage>2314</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-06288-9</pub-id><pub-id pub-id-type="pmid">33140181</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepens</surname><given-names>T</given-names></name><name><surname>Dres</surname><given-names>M</given-names></name><name><surname>Heunks</surname><given-names>L</given-names></name><name><surname>Goligher</surname><given-names>EC</given-names></name></person-group>. <article-title>Diaphragm-protective mechanical ventilation.</article-title> <source>Curr Opin Crit Care</source>. <year>2019</year>;<volume>25</volume>(<issue>1</issue>):<fpage>77</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000578</pub-id><pub-id pub-id-type="pmid">30531536</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrof</surname><given-names>BJ</given-names></name><name><surname>Hussain</surname><given-names>SN</given-names></name></person-group>. <article-title>Ventilator-induced diaphragmatic dysfunction: what have we learned?</article-title> <source>Curr Opin Crit Care</source>. <year>2016</year>;<volume>22</volume>:<fpage>67</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000272</pub-id><pub-id pub-id-type="pmid">26627540</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pe&#x00F1;uelas</surname><given-names>O</given-names></name><name><surname>Keough</surname><given-names>E</given-names></name><name><surname>L&#x00F3;pez-Rodr&#x00ED;guez</surname><given-names>L</given-names></name><name><surname>Carriedo</surname><given-names>D</given-names></name><name><surname>Gon&#x00E7;alves</surname><given-names>G</given-names></name><name><surname>Barreiro</surname><given-names>E</given-names></name><etal/></person-group> <article-title>Ventilator-induced diaphragm dysfunction: translational mechanisms lead to therapeutical alternatives in the critically ill.</article-title> <source>Intensive Care Med Exp</source>. <year>2019</year>;<volume>7</volume> <supplement>Suppl 1</supplement>:<fpage>48</fpage>. <pub-id pub-id-type="doi">10.1186/s40635-019-0259-9</pub-id><pub-id pub-id-type="pmid">31346802</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supinski</surname><given-names>GS</given-names></name><name><surname>Morris</surname><given-names>PE</given-names></name><name><surname>Dhar</surname><given-names>S</given-names></name><name><surname>Callahan</surname><given-names>LA</given-names></name></person-group>. <article-title>Diaphragm Dysfunction in Critical Illness.</article-title> <source>Chest</source>. <year>2018</year>;<volume>153</volume>(<issue>4</issue>):<fpage>1040</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2017.08.1157</pub-id><pub-id pub-id-type="pmid">28887062</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x00E9;duneau</surname><given-names>G</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>Schortgen</surname><given-names>F</given-names></name><name><surname>Piquilloud</surname><given-names>L</given-names></name><name><surname>Zogheib</surname><given-names>E</given-names></name><name><surname>Jonas</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Epidemiology of Weaning Outcome according to a New Definition. The WIND Study.</article-title> <source>Am J Respir Crit Care Med</source>. <year>2017</year>;<volume>195</volume>(<issue>6</issue>):<fpage>772</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201602-0320OC</pub-id><pub-id pub-id-type="pmid">27626706</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetrugno</surname><given-names>L</given-names></name><name><surname>Guadagnin</surname><given-names>GM</given-names></name><name><surname>Barbariol</surname><given-names>F</given-names></name><name><surname>Langiano</surname><given-names>N</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Bove</surname><given-names>T</given-names></name></person-group>. <article-title>Ultrasound Imaging for Diaphragm Dysfunction: A Narrative Literature Review.</article-title> <source>J Cardiothorac Vasc Anesth</source>. <year>2019</year>;<volume>33</volume>(<issue>9</issue>):<fpage>2525</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1053/j.jvca.2019.01.003</pub-id><pub-id pub-id-type="pmid">30686657</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haaksma</surname><given-names>ME</given-names></name><name><surname>Tuinmana</surname><given-names>PR</given-names></name><name><surname>Heunksa</surname><given-names>L</given-names></name></person-group>. <article-title>Weaning the patient: between protocols and physiology.</article-title> <source>Curr Opin Crit Care</source>. <year>2021</year>;<volume>27</volume>:<fpage>29</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000790</pub-id><pub-id pub-id-type="pmid">33337620</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="other">Ghiani A, Paderewska J, Sainis A, Crispin A, Walcher S, Neurohr C. Variables predicting weaning outcome in prolonged mechanically ventilated tracheotomized patients: a retrospective study. J Intens Care. 2020;21;8:19.</mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>S</given-names></name><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Lerner</surname><given-names>DP</given-names></name></person-group>. <article-title>Review of Critical Illness Myopathy and Neuropathy.</article-title> <source>Neurohospitalist</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>41</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1941874416663279</pub-id><pub-id pub-id-type="pmid">28042370</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrholz</surname><given-names>J</given-names></name><name><surname>Pohl</surname><given-names>M</given-names></name><name><surname>Kugler</surname><given-names>J</given-names></name><name><surname>Burridge</surname><given-names>J</given-names></name><name><surname>M&#x00FC;ckel</surname><given-names>S</given-names></name><name><surname>Elsner</surname><given-names>B</given-names></name></person-group>. <article-title>Physical rehabilitation for critical illness myopathy and neuropathy.</article-title> <source>Cochrane Database Syst Rev</source>. <year>2015</year>; (<issue>3</issue>):<elocation-id>CD010942</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD010942.pub2</pub-id><pub-id pub-id-type="pmid">25737049</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name></person-group>. <article-title>Is Mitochondrial Oxidative Stress the Key Contributor to Diaphragm Atrophy and Dysfunction in Critically Ill Patients.</article-title> <source>Crit Care Res Pract</source>. <year>2020</year>;<volume>2020</volume>:<elocation-id>8672939</elocation-id>. <pub-id pub-id-type="doi">10.1155/2020/8672939</pub-id><pub-id pub-id-type="pmid">32377432</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber-Carstens</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Wollersheim</surname><given-names>T</given-names></name><name><surname>Assmann</surname><given-names>A</given-names></name><name><surname>Bierbrauer</surname><given-names>J</given-names></name><name><surname>Marg</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Critical illness myopathy and GLUT4: significance of insulin and muscle contraction.</article-title> <source>Am J Respir Crit Care Med</source>. <year>2013</year>;<volume>187</volume>(<issue>4</issue>):<fpage>387</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201209-1649OC</pub-id><pub-id pub-id-type="pmid">23239154</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llano-Diez</surname><given-names>M</given-names></name><name><surname>Fury</surname><given-names>W</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Gromada</surname><given-names>J</given-names></name><name><surname>Larsson</surname><given-names>L</given-names></name></person-group>. <article-title>RNA-sequencing reveals altered skeletal muscle contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy.</article-title> <source>Skelet Muscle</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>9</fpage>. <pub-id pub-id-type="doi">10.1186/s13395-019-0194-1</pub-id><pub-id pub-id-type="pmid">30992050</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeseler</surname><given-names>G</given-names></name><name><surname>Foadi</surname><given-names>N</given-names></name><name><surname>Wiegand</surname><given-names>E</given-names></name><name><surname>Ahrens</surname><given-names>J</given-names></name><name><surname>Krampfl</surname><given-names>K</given-names></name><name><surname>Dengler</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials.</article-title> <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>(<issue>4</issue>):<fpage>1239</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e31816a02cf</pub-id><pub-id pub-id-type="pmid">18379251</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>MB</given-names></name><name><surname>Moylan</surname><given-names>JS</given-names></name></person-group>. <article-title>Beyond atrophy: redox mechanisms of muscle dysfunctionin chronic inflammatory disease.</article-title> <source>J Physiol</source>. <year>2011</year>;<volume>589</volume>:<fpage>2171</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2010.203356</pub-id><pub-id pub-id-type="pmid">21320886</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>CC</given-names></name><name><surname>Batt</surname><given-names>J</given-names></name></person-group>. <article-title>ICU-acquired weakness: mechanisms of disability.</article-title> <source>Curr Opin Crit Care</source>. <year>2012</year>;<volume>18</volume>:<fpage>509</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0b013e328357cb5e</pub-id><pub-id pub-id-type="pmid">22918258</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>SD</given-names></name><name><surname>Patel</surname><given-names>BK</given-names></name></person-group>. <article-title>Evolving targets for sedation during mechanical ventilation.</article-title> <source>Curr Opin Crit Care</source>. <year>2020</year>;<volume>26</volume>(<issue>1</issue>):<fpage>47</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000687</pub-id><pub-id pub-id-type="pmid">31764193</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>DA</given-names></name><name><surname>de Bettignies</surname><given-names>AM</given-names></name><name><surname>Seemann</surname><given-names>R</given-names></name><name><surname>Krenn</surname><given-names>CG</given-names></name><name><surname>Roth</surname><given-names>AR</given-names></name></person-group>. <article-title>Impact of a remifentanil supply shortage on mechanical ventilation in a tertiary care hospital: a retrospective comparison.</article-title> <source>Crit Care</source>. <year>2018</year>;<volume>22</volume>(<issue>1</issue>):<fpage>267</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-018-2198-3</pub-id><pub-id pub-id-type="pmid">30367645</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kuriyama</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Effect of dexmedetomidine on delirium during sedation in adult patients in intensive care units: A systematic review and meta-analysis.</article-title> <source>J Clin Anesth</source>. <year>2021</year>;<volume>69</volume>:<elocation-id>110157</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jclinane.2020.110157</pub-id><pub-id pub-id-type="pmid">33296787</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Belley-Cote</surname><given-names>E</given-names></name><name><surname>M&#x00F8;ller</surname><given-names>MH</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><etal/></person-group> <article-title>Neuromuscular blockade in patients with ARDS: a rapid practice guideline.</article-title> <source>Intensive Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>11</issue>):<fpage>1977</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-06227-8</pub-id><pub-id pub-id-type="pmid">33104824</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hraiech</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Duggal</surname><given-names>A</given-names></name><name><surname>Fanelli</surname><given-names>V</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Myorelaxants in ARDS patients.</article-title> <source>Intensive Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>12</issue>):<fpage>2357</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-06297-8</pub-id><pub-id pub-id-type="pmid">33159530</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renew</surname><given-names>JR</given-names></name><name><surname>Ratzlaff</surname><given-names>R</given-names></name><name><surname>Hernandez-Torres</surname><given-names>V</given-names></name><name><surname>Brull</surname><given-names>SJ</given-names></name><name><surname>Prielipp</surname><given-names>RC</given-names></name></person-group>. <article-title>Neuromuscular blockade management in the critically Ill patient.</article-title> <source>J Intensive Care</source>. <year>2020</year>;<volume>8</volume>:<fpage>37</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-020-00455-2</pub-id><pub-id pub-id-type="pmid">32483489</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>KS</given-names></name><name><surname>Patel</surname><given-names>BK</given-names></name><name><surname>MacKenzie</surname><given-names>EL</given-names></name><name><surname>Giovanni</surname><given-names>SP</given-names></name><name><surname>Pohlman</surname><given-names>AS</given-names></name><name><surname>Churpek</surname><given-names>MM</given-names></name><etal/></person-group> <article-title>Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients.</article-title> <source>Chest</source>. <year>2018</year>;<volume>154</volume>(<issue>4</issue>):<fpage>781</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2018.07.016</pub-id><pub-id pub-id-type="pmid">30217640</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doorduin</surname><given-names>J</given-names></name><name><surname>Sinderby</surname><given-names>CA</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Stegeman</surname><given-names>DF</given-names></name><name><surname>van Hees</surname><given-names>HW</given-names></name><name><surname>van der Hoeven</surname><given-names>JG</given-names></name><etal/></person-group> <article-title>The calcium sensitizer levosimendan improves human diaphragm function.</article-title> <source>Am J Respir Crit Care Med</source>. <year>2012</year>;<volume>185</volume>(<issue>1</issue>):<fpage>90</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201107-1268OC</pub-id><pub-id pub-id-type="pmid">21960535</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaltsi</surname><given-names>I</given-names></name><name><surname>Angelopoulos</surname><given-names>E</given-names></name><name><surname>Tzanis</surname><given-names>G</given-names></name><name><surname>Sideris</surname><given-names>A</given-names></name><name><surname>Tyrovolas</surname><given-names>K</given-names></name><name><surname>Kokkoris</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Contribution of Levosimendan in Weaning from Mechanical Ventilation in Patients with Left Ventricular Dysfunction: A Pilot Study.</article-title> <source>Crit Care Res Pract</source>. <year>2019</year>;<volume>2019</volume>:<elocation-id>7169492</elocation-id>. <pub-id pub-id-type="doi">10.1155/2019/7169492</pub-id><pub-id pub-id-type="pmid">31428473</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoba</surname><given-names>M</given-names></name><name><surname>Katagiri</surname><given-names>M</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Takakura</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Kurosaki</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Aminophylline increases respiratory muscle activity during hypercapnia in humans.</article-title> <source>Pulm Pharmacol Ther</source>. <year>2015</year>;<volume>30</volume>:<fpage>96</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.pupt.2014.03.006</pub-id><pub-id pub-id-type="pmid">24721495</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Huh</surname><given-names>JW</given-names></name><name><surname>Hong</surname><given-names>SB</given-names></name><name><surname>Koh</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Effect of theophylline on ventilator-induced diaphragmatic dysfunction.</article-title> <source>J Crit Care</source>. <year>2016</year>;<volume>33</volume>:<fpage>145</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2016.01.007</pub-id><pub-id pub-id-type="pmid">26948253</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetrugno</surname><given-names>L</given-names></name><name><surname>Guadagnin</surname><given-names>GM</given-names></name><name><surname>Barbariol</surname><given-names>F</given-names></name><name><surname>Langiano</surname><given-names>N</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Bove</surname><given-names>T</given-names></name></person-group>. <article-title>Ultrasound Imaging for Diaphragm Dysfunction: A Narrative Literature Review.</article-title> <source>J Cardiothorac Vasc Anesth</source>. <year>2019</year>;<volume>33</volume>(<issue>9</issue>):<fpage>2525</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1053/j.jvca.2019.01.003</pub-id><pub-id pub-id-type="pmid">30686657</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Spadaro</surname><given-names>S</given-names></name><name><surname>Goligher</surname><given-names>EC</given-names></name></person-group>. <article-title>Monitoring Patient Respiratory Effort During Mechanical Ventilation: Lung and Diaphragm-Protective Ventilation.</article-title> <source>Crit Care</source>. <year>2020</year>;<volume>24</volume>(<issue>1</issue>):<fpage>106</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-2777-y</pub-id><pub-id pub-id-type="pmid">32204729</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Dres</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Scales</surname><given-names>DC</given-names></name><name><surname>Herridge</surname><given-names>MS</given-names></name><etal/></person-group> <article-title>Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes.</article-title> <source>Am J Respir Crit Care Med</source>. <year>2018</year>;<volume>197</volume>(<issue>2</issue>):<fpage>204</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201703-0536OC</pub-id><pub-id pub-id-type="pmid">28930478</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>E</given-names></name><name><surname>Mauri</surname><given-names>T</given-names></name><name><surname>Beitler</surname><given-names>JR</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name></person-group>. <article-title>Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions.</article-title> <source>Intensive Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>4</issue>):<fpage>606</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05942-6</pub-id><pub-id pub-id-type="pmid">32016537</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kacmarek</surname><given-names>RM</given-names></name></person-group>. <article-title>Proportional assist ventilation and neurally adjusted ventilatory assist.</article-title> <source>Respir Care</source>. <year>2011</year>;<volume>56</volume>(<issue>2</issue>):<fpage>140</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4187/respcare.01021</pub-id><pub-id pub-id-type="pmid">21333175</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>E</given-names></name><name><surname>Mauri</surname><given-names>T</given-names></name><name><surname>Beitler</surname><given-names>JR</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name></person-group>. <article-title>Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions.</article-title> <source>Intensive Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>4</issue>):<fpage>606</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05942-6</pub-id><pub-id pub-id-type="pmid">32016537</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkey</surname><given-names>AJ</given-names></name><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Del Sorbo</surname><given-names>L</given-names></name><name><surname>Hodgson</surname><given-names>CL</given-names></name><name><surname>Adhikari</surname><given-names>NKJ</given-names></name><name><surname>Wunsch</surname><given-names>H</given-names></name><etal/></person-group> <article-title>Low Tidal Volume versus Non-Volume-Limited Strategies for Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.</article-title> <source>Ann Am Thorac Soc</source>. <year>2017</year>;<volume>14</volume> <supplement>Supplement_4</supplement>:<fpage>S271</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201704-337OT</pub-id><pub-id pub-id-type="pmid">28846440</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putensen</surname><given-names>C</given-names></name><name><surname>Theuerkauf</surname><given-names>N</given-names></name><name><surname>Zinserling</surname><given-names>J</given-names></name><name><surname>Wrigge</surname><given-names>H</given-names></name><name><surname>Pelosi</surname><given-names>P</given-names></name></person-group>. <article-title>Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury.</article-title> <source>Ann Intern Med</source>. <year>2009</year>;<volume>151</volume>(<issue>8</issue>):<fpage>566</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-151-8-200910200-00011</pub-id><pub-id pub-id-type="pmid">19841457</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battaglini</surname><given-names>D</given-names></name><name><surname>Sottano</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>L</given-names></name><name><surname>Robba</surname><given-names>C</given-names></name><name><surname>Rocco</surname><given-names>P</given-names></name><name><surname>Pelosi</surname><given-names>P</given-names></name></person-group>. <article-title>Ten golden rules for individualized mechanical ventilation in acute respiratory distress syndrome.</article-title> <source>J Intern Med</source>. <year>2021</year>; (<comment>Article in press</comment>)</mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robba</surname><given-names>C</given-names></name><name><surname>Battaglini</surname><given-names>D</given-names></name><name><surname>Ball</surname><given-names>L</given-names></name><name><surname>Patroniti</surname><given-names>N</given-names></name><name><surname>Loconte</surname><given-names>M</given-names></name><name><surname>Brunetti</surname><given-names>I</given-names></name><etal/></person-group> <article-title>Distinct phenotypes require distinct respiratory management strategies in severe COVID-19.</article-title> <source>Respir Physiol Neurobiol</source>. <year>2020</year>;<volume>279</volume>:<elocation-id>103455</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.resp.2020.103455</pub-id><pub-id pub-id-type="pmid">32437877</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelosi</surname><given-names>P</given-names></name><name><surname>Brazzi</surname><given-names>L</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name></person-group>. <article-title>Prone position in acute respiratory distress syndrome.</article-title> <source>Eur Respir J</source>. <year>2002</year>;<volume>20</volume>:<fpage>1017</fpage>. <pub-id pub-id-type="doi">10.1183/09031936.02.00401702</pub-id><pub-id pub-id-type="pmid">12412699</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
